SLC5A2 and hydrops fetalis: Further, a limitation of this study is that the HF cohort did not receive sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, or angiotensin receptor-neprilysin inhibitors, as recruitment occurred between 2011 and 2014, prior to their clinical adoption.